Early Research Suggests Triple Therapy Could Clear HIV in Newborns

Combination therapy with broadly neutralizing antibodies, antiretroviral therapy and CCR5 blockade limits viral reservoir seeding in infant macaque model of HIV

Lack of access to antiretroviral therapy (ART) leads to the transmission of human immunodeficiency virus in ~120,000 children annually, emphasizing the need for new strategies to prevent lifelong infection. Here in an infant rhesus macaque model of peripartum oral infection, we show that broadly neutralizing antibodies directed to the viral envelope protein were insufficient to prevent latent reservoir establishment, independent of daily ART. Bl…

HIV-1 proviruses may drive chronic systemic inflammation

HIV (human immunodeficiency virus) is a virus that attacks the body's immune system and remains a major global health challenge because of persistent viral reservoirs, despite effective treatments. Key factors include around 40 million people living with HIV, 1 million new infections each year and permanent viral DNA integration into host cells. Some HIV proviruses hide quietly in cells and escape both medicines and the immune system, creating a permanent viral reservoir that prevents patients from being cured.

Early Research Suggests Triple Therapy Could Clear HIV in Newborns

Research carried out in infant macaques suggests that treatment with antiretroviral therapy plus three antibody therapies could permanently clear human immunodeficiency virus (HIV) from the body of infected newborn babies. The treatment used by the investigators combined antiretroviral therapy with two broadly neutralizing antibodies that target the viral envelope, as well as leronlimab, an antibody that blocks CCR5, a cell-surface co-receptor u…

New combination therapy could permanently clear HIV in newborns

Every year, more than 120,000 newborns worldwide contract HIV, a global health burden that requires lifelong treatment for millions of people - assuming they have access and can afford it.

Study: Triple-dose regimen may permanently clear HIV in infected newborns

Every year, more than 120,000 newborns worldwide contract HIV, a global health burden that requires lifelong treatment for millions of people — assuming they have access and can afford it. New research led by Oregon Health & Science University suggests another possibility: a one-time regimen of therapies given to newborns within three days of birth to permanently clear the virus. The research was published in the journal Nature Microbiology. “Th…

New D3 (PENTA-21) findings add reassurance about simplified HIV treatment for children

New results from the D3 (PENTA-21) trial, sponsored by Fondazione Penta ETS, add to the evidence that dolutegravir-based treatment remains a strong option for children living with HIV, even when the HIV virus had mutated and was resistant to other non dolutegravir-based medications. In the nested pharmacokinetic sub-study, which explored how the drugs moved through